A Current Perspective of Two of the Most Aggressive Head and Neck Cancers: Pharyngeal and Laryngeal

TL;DR

This review discusses pharyngeal and laryngeal cancers, highlighting their aggressive nature, risk factors, and the need for early detection and improved treatments.

Contribution

The paper provides a comprehensive overview of risk factors, diagnostic challenges, and treatment options for two aggressive head and neck cancers.

Findings

Pharyngeal and laryngeal cancers are often diagnosed at advanced stages and have high mortality rates.

Current treatments include surgery, radiotherapy, chemotherapy, and immunotherapy, but survival rates remain unsatisfactory.

Early detection and personalized treatment strategies are critical for improving outcomes in these cancers.

Abstract

Pharyngeal and laryngeal cancers are two of the most aggressive forms of head and neck cancer, often diagnosed in advanced stages and associated with high mortality. This review provides an overview of the main risk factors, such as tobacco, alcohol, HPV infection, and dietary habits, as well as typical symptoms and diagnostic challenges. The review also discusses current treatment options, including surgery, radiotherapy, chemotherapy, and immunotherapy. Early detection remains crucial, particularly for cancers that currently lack established screening protocols.

Background: Head and neck cancers (HNCs) represent a substantial global health burden, with an estimated mortality rate exceeding 50% annually. Among the various subsites, pharyngeal and laryngeal carcinomas are recognized as two of the most aggressive and challenging forms, characterized by high incidence, poor prognosis, and a strong association with advanced-stage diagnosis. Methods: A systematic literature review was performed using electronic literature databases (e.g., PubMed, Google Scholar). Search terms included “head and neck cancer”, “laryngeal cancer”, and “pharyngeal cancer”. Selected studies are published within the last two decades. Results: Laryngeal cancer constitutes approximately 40% of head and neck malignancies, with a clear male predominance, and pharyngeal cancer shows increased incidence in male populations from the Americas and Africa. Despite therapeutic advancements in radiotherapy, chemotherapy, and immunotherapy, overall survival rates remain unsatisfactory. Moreover, patients are at increased risk for second primary malignancies, particularly within the lungs and esophagus, due to the widespread carcinogenic exposure along the aerodigestive tract. Conclusions: To mitigate the morbidity and mortality associated with pharyngeal and laryngeal cancers, early detection, risk factor mitigation, and public health education are imperative. Enhancing screening among high-risk populations and adopting personalized, multidisciplinary treatment strategies may significantly improve clinical outcomes and long-term survival.

Figures